Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson’s disease management
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Drug Delivery"
DOI: 10.1080/17425247.2020.1779218
Abstract: ABSTRACT Introduction α-synuclein (SNCA), a major component of Lewy body is a pathological hallmark of Parkinson’s disease (PD). Mutations in the SNCA gene cause misfolding and aggregation of SNCA protein, which results in neurodegeneration. Several… read more here.
Keywords: 2ar agonists; drug delivery; delivery; gene expression ... See more keywords
Intronic enhancers of the human SNCA gene predominantly regulate its expression in brain in vivo
Sign Up to like & getrecommendations! Published in 2022 at "Science Advances"
DOI: 10.1126/sciadv.abq6324
Abstract: Evidence from patients with Parkinson’s disease (PD) and our previously reported α-synuclein (SNCA) transgenic rat model support the idea that increased SNCA protein is a substantial risk factor of PD pathogenesis. However, little is known… read more here.
Keywords: brain vivo; intronic enhancers; brain; snca gene ... See more keywords
Genetic Analysis and Literature Review of SNCA Variants in Parkinson's Disease
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Aging Neuroscience"
DOI: 10.3389/fnagi.2021.648151
Abstract: Parkinson's disease (PD) is the fastest-growing neurodegenerative disorder. Aging, environmental factors, and genetics are considered as risk factors. The alpha-synuclein gene (SNCA), the first pathogenic gene identified in a familial form of PD, was indisputably… read more here.
Keywords: gene; parkinson disease; snca gene; literature review ... See more keywords